



ONE GOAL: Identify a Treatment for ALS & Enhance Care Resources

ALSONE.org



ONESCIENCE GOAL

The ALS ONE team has identified the strongest therapeutic opportunities in ALS and are working together as partners to expedite progress with the goal of finding a treatment within four years, through the sharing of ideas and division of responsibility to advance research projects forward.

ONECARE GOAL

A percentage of funds will be used to improve care for those impacted by ALS, including: increased access to ALS clinics as well as support, technology, transportation and education initiatives.

ONENEED

The ALS ONE scientific plan is milestone driven, and will require significant funding to advance. A percentage of funds raised will be directed to assist patients with the many needs they will face until a treatment is available.

ONEPLAN

To raise funds through:

- Major gifts
- Small business partnerships
- Non-profit alliances
- Corporate sponsorships
- ALS ONE Month (May 2016)

ONEORIGIN




Kevin Gosnell
Founder and Director of ALS ONE & Founder and Director of ALS Knights

When Kevin Gosnell was diagnosed with ALS in May of 2015, his world abruptly turned upside down and life as he knew it changed forever. He learned there is no treatment, and very few resources available to educate him on the disease. As a successful small business CEO and mentor, he immediately put his leadership skills to work, convening the best minds in the ALS community with the goal of a partnership to accelerate progress toward finding a treatment and providing better care to those living with the disease. Through ALS ONE, his vision is now a reality.

ONETEAM

The top leaders in ALS have banded together to leverage the strengths of their venerable institutions with the goal of bringing treatment to patients within four years and improving care for all impacted by ALS. The team:




Dr. Robert Brown Jr., MD, DPhil
Professor and Chair of Neurology at the University of Massachusetts Medical Center and Medical School



Dr. Merit Cudkowicz, MD, MSc
Julianne Dorn Professor of Neurology at Harvard Medical School, Chief of Neurology Service at Massachusetts General Hospital



Dr. Steve Perrin, Ph.D.
Chief Executive Officer and Chief Scientific Officer at the ALS Therapy Development Institute (ALS TDI) in Cambridge, MA



Ron Hoffman
Co-founder of the Gordon T. Heald ALS fund, Founder and Director of Compassionate Care ALS, the author of "Sacred Bullet: Transforming Trauma to Grace while Tending the Terminally Ill"



Dr. Nazem Atassi, MD
Associate Director of the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH), Assistant Professor of Neurology at Harvard Medical School



Dr. James Berry, MD
Associate Director of the Neurological Clinical Research Institute (NCRI), Assistant Professor of Neurology at Harvard Medical School, Co-Director of the MGH Neuromuscular Division and of the MGH ALS Unit



SUPPORTERS

